GSEA of the tumors from Braf/Pten mice treated with SX-682 revealed a significant increase in CD8 + T cell activation, with trends toward increased T cell-mediated immune response to the tumor, immune response to tumor, adaptive immune response, antigen processing and presentation, CD4 + T cell activation, stem cell differentiation, CD8 + T cell proliferation, T cell-mediated cytotoxicity, and lymphocyte activation. Here, CD8A is linked to neoplasm.